As President of the Japanese Society of Clinical Neuropsychopharmacology (JSCNP), I am honored to extend my formal greetings. In October 2024, I was appointed as the 12th President of JSCNP. Together with Vice President Koichiro Watanabe, the Board of Directors, councilors, and society members, I am committed to advancing the Society’s objectives and fostering its continued development. I respectfully seek your ongoing support and collaboration in these endeavors.
The Japanese Society of Clinical Neuropsychopharmacology (JSCNP), established in 1991, has consistently pursued the advancement of psychiatric pharmacotherapy. Currently, the Society comprises over 1,500 members, including numerous esteemed researchers, such as university professors. The Society also places significant emphasis on the education and training of emerging researchers and clinicians.
Clinical neuropsychopharmacology represents a scientific discipline dedicated to the pursuit of “rational drug therapy” within the domain of neuropsychiatry. This entails the provision of the most appropriate pharmacological intervention to specific patient populations, with optimal dosage and administration methods, guided by robust evidence. The Society’s mission is to establish evidence-based psychiatric pharmacotherapy through rigorous examination of the safety and efficacy of psychotropic medications. The scope of research encompasses a wide array of fields, including pharmacokinetics, pharmacodynamics, drug interactions, genomic pharmacology, treatment guidelines, adverse events, and clinical trials for the development of psychotropic agents.
JSCNP-certified specialists, recognized by the Japanese Society of Neuropsychiatry as subspecialists in psychiatry, possess advanced expertise in these domains and are dedicated to the practice of sophisticated psychiatric pharmacotherapy.
The Society’s principal activities include the organization of annual scientific meetings and specialized seminars, the publication of peer-reviewed academic journals, the training and certification of neuropsychopharmacology specialists, and the conferment of the Paul Janssen Prize for outstanding research contributions. Furthermore, the Society offers overseas training programs to enhance international collaboration and knowledge exchange. Looking ahead, the Society aims to strengthen its educational initiatives through the expansion of e-learning platforms and online training programs. Additionally, we are committed to the production of authoritative academic textbooks, evidence-based pharmacotherapy guidelines, and expert consensus documents to support clinical practice.
In collaboration with the Japanese Society of Neuropsychopharmacology, we endeavor to contribute to the refinement of psychiatric drug therapy. The Society actively engages with academia, industry, and governmental agencies, thereby demonstrating its leadership and influence across these sectors.
We sincerely appreciate your continued understanding and support as we advance the Society’s mission.

Norio Yasui-Furukori
President
The Japanese Society of Clinical Neuropsychopharmacology